Gene editing offers hope for blood disorder patients
NCT ID NCT06328764
First seen Feb 10, 2026 · Last updated May 29, 2026 · Updated 18 times
Summary
This early-stage study tests a new gene-edited stem cell treatment (CS-101) for people with beta-thalassemia, a serious blood disorder. The goal is to see if the treatment is safe and can help patients stop needing regular blood transfusions. The study involves 10 participants aged 6 to 35 who will receive their own genetically modified stem cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BETA-THALASSEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China
Conditions
Explore the condition pages connected to this study.